The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.
Daisuke KuraiAkiko MizukamiVictor PrecklerFrederik VerelstDaniel MolnarTaizo MatsukiYufan HoAtaru IgarashiPublished in: Expert review of vaccines (2024)
RSVPreF3 OA vaccination is projected to have a substantial public health impact by reducing RSV-related morbidity and mortality in the OA population.